404-777-1551
CLIA 11D2099839CAP 9385008
PillarsDx

Why PFAS Testing Accuracy Matters — And What Higher-Purity Reference Standards Mean for Patient Health

Why PFAS Testing Accuracy Matters — And What Higher-Purity Reference Standards Mean for Patient Health

If you've been following health and environmental news lately, you've almost certainly encountered the term PFAS — per- and polyfluoroalkyl substances, often called "forever chemicals." These synthetic compounds don't break down in the environment or in our bodies, and mounting research links them to thyroid disease, kidney dysfunction, immune suppression, and certain cancers.

Here's the thing: detecting PFAS at meaningful levels — and doing so accurately — is one of the most demanding analytical challenges facing labs today. And a quiet but significant shift is underway in how we ensure that accuracy. Let's talk about why it matters, what's changing, and how it connects to chronic disease management and patient monitoring.

What Are PFAS, and Why Should Healthcare Providers Care?

PFAS are a family of thousands of chemicals used since the 1950s in everything from nonstick cookware to firefighting foam. They persist in water, soil, and — critically — in human blood. The CDC's National Health and Nutrition Examination Survey (NHANES) has found detectable levels of several PFAS compounds in the blood of nearly all Americans tested.

From a clinical perspective, PFAS exposure is associated with:

  • Elevated cholesterol and cardiovascular risk
  • Thyroid hormone disruption
  • Reduced kidney function
  • Immune response suppression (including reduced vaccine efficacy)
  • Increased risk of certain cancers, particularly kidney and testicular

For providers managing chronic conditions — especially those using Remote Patient Monitoring to track trends over time — understanding the environmental contributors to patient health is increasingly important. You can't manage what you can't measure, and you can't measure what you can't test accurately.

The Problem with Imprecise Testing

PFAS testing in both environmental and clinical settings depends on reference standards — highly characterized chemical samples that labs use to calibrate instruments and validate results. Think of them as the ruler against which every measurement is compared.

If your ruler is off by even a small margin, every measurement derived from it carries that error forward. In PFAS testing, where we're often looking at concentrations in the parts-per-trillion range, even tiny impurities in a reference standard can:

  • Create false positives or negatives in water testing
  • Skew biomonitoring results in clinical blood panels
  • Undermine regulatory compliance data
  • Erode confidence in longitudinal patient data

This is not a theoretical concern. Labs have reported batch-to-batch variability in reference materials that introduces uncertainty precisely where certainty is needed most.

The Push Toward Higher-Purity Standards

The analytical chemistry community is responding. There's a clear movement toward reference standards with verified purity at or above 99.8%, combined with rigorous documentation of long-term batch consistency.

What does this look like in practice?

  • Higher purity thresholds: Moving from the traditional 95-98% purity range to 99.8%+ ensures that calibration curves are tighter and results are more reproducible.
  • Long-term batch consistency: Labs need to know that the standard they use today will behave identically to the one they use six months from now. Consistent lot-to-lot performance is essential for trending data over time.
  • Lab-driven portfolios: Rather than offering a handful of generic PFAS compounds, leading suppliers are building comprehensive catalogs that match the analyte lists in EPA Method 533, EPA Method 537.1, and emerging clinical biomonitoring panels.

Companies like Restek have recently redefined the benchmark in this space — achieving 99.8% pure reference standards with documented batch consistency and an expansive, lab-driven portfolio. This kind of advancement might seem niche, but its downstream effects are significant.

Why This Matters for Chronic Care and Remote Monitoring

You might be wondering: what does analytical chemistry have to do with RPM and chronic care management?

More than you'd think.

Chronic conditions linked to PFAS exposure — thyroid disorders, cardiovascular disease, kidney disease — are among the most common conditions managed through Remote Patient Monitoring programs. When we track a patient's eGFR trending downward, or notice thyroid hormone levels drifting despite medication adherence, environmental exposure data can provide critical context.

As clinical PFAS biomonitoring becomes more accessible (and more accurate, thanks to better reference standards), we can anticipate a future where:

  1. Exposure data informs care plans — Providers can contextualize chronic disease progression with environmental exposure history.
  2. Population health insights improve — Aggregated, accurate PFAS data helps identify at-risk communities and allocate monitoring resources.
  3. Longitudinal accuracy supports trending — Just as RPM depends on consistent device calibration to track blood pressure or glucose over time, biomonitoring depends on consistent reference standards to track chemical exposure over time.

At KaiCare, we think about data integrity constantly. Our RPM and CCM platforms are built on the principle that reliable, consistent data drives better clinical decisions. The same principle applies to the labs generating the exposure data that may soon feed into holistic patient profiles.

What Providers and Health Systems Can Do Now

Even as the testing landscape evolves, there are practical steps you can take today:

  • Stay informed on PFAS health guidance: The EPA, ATSDR, and state health departments are regularly updating exposure thresholds and clinical recommendations.
  • Ask about testing methodology: If you're ordering PFAS blood panels for patients, understand what reference standards the lab uses and whether they meet current best practices.
  • Consider environmental context in chronic care: For patients with unexplained disease progression — particularly thyroid, kidney, or immune-related conditions — environmental exposure may be a missing piece of the puzzle.
  • Leverage technology for longitudinal tracking: Whether it's biometric data from RPM devices or lab values from periodic testing, trending over time reveals what single snapshots cannot.

The Bigger Picture

The push for higher-purity PFAS reference standards isn't just an analytical chemistry story — it's a public health story. Accurate testing underpins regulatory action, clinical decision-making, and ultimately patient outcomes.

As healthcare moves toward more proactive, data-driven models — exactly the kind of care that RPM and CCM enable — the quality of upstream data becomes everyone's concern. Better reference standards mean better lab results. Better lab results mean better clinical context. Better clinical context means better care.

At KaiCare, we believe that the future of healthcare depends on connecting these dots: from the laboratory bench to the patient's bedside (or living room). Whether we're talking about a blood pressure cuff transmitting daily readings or a reference standard ensuring a PFAS result is accurate to the parts-per-trillion level, the principle is the same.

Precision matters. Consistency matters. And patients deserve both.

Interested in how Remote Patient Monitoring can help you manage chronic conditions with greater confidence and better data? [Learn more about KaiCare's RPM and CCM solutions.]